Director, Clinical Quality
Revolution Medicines - Redwood City, California, United States
Posted Apr 10, 2026
Benefits
- Parental leave
- Not verified
- Non-birth-parent leave
- Not verified
- Family-building benefits
-
- Fertility benefits: Not verified
- Adoption assistance: Not verified
- Surrogacy assistance: Not verified
- Mental health support
- Not verified
- Relocation assistance
- Not verified
- Childcare support
- Not verified
- Learning budget
- Not verified
- Verification
- Not verified
- Salary
- $201K-$251K not verified - source not recorded; timestamp not recorded
- 401(k) match
- Not verified
Was this benefit information wrong? Tell us.
Market context
- U.S. role benchmark (BLS OEWS)
- $81,444 U.S. median for this role
- Projected growth (BLS Employment Projections)
- +6.9% - Faster than average
177% above the BLS role benchmark for healthcare aggregate.
Matched to SOC 29-1141 - Healthcare aggregate by role bucket.
Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.
Schedule
- Shift type
- Not verified
- Weekend work
- Not verified
Application
- Cover letter
- Not verified
- Assessment
- Not verified
- Deadline
- Not stated
Where they hire
State eligibility is not yet verified.
About this role
Director, Clinical Quality Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director of Clinical Quality will play a key role in Quality Assurance and have direct responsibility for the clinical quality workstreams and study teams. This role is responsible for providing quality and compliance oversight for RevMed-sponsored clinical trials with respect to RevMed's Standard Operating Procedures, applicable regulatory requirements (FDA, EU, ICH & country-specific), and current industry standards and practices. This role will support daily compliance operational activities, evaluate risk, and resolve quality events for early phase through late-phase clinical programs. This role will also be responsible for managing multiple studies including GLP activities that impact clinical studies/data. This role will report to the Head of Clinical Quality. - Act as the study lead for Phase 3 program(s), provide support and guidance to the Clinical Development and Clinical Operations functions, including but not limited to the following functional areas: Global Patient Safety, Translational Medicine,
Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.
Apply link not verified; last-live date unavailable.
What verified means
Verified means a displayed claim has recorded source fields, a user-resolvable source, and a full check date.
Related jobs
-
Senior Director, Clinical Quality Assurance
Alkermes - Waltham, MA, United States
-
Associate Director, Medical Writing
Alkermes - Waltham, MA, United States
-
Director, Clinical Pharmacology
Alkermes - Waltham, MA, United States
-
Sr. Director, Clinical Supply Chain
Alkermes - Waltham, MA, United States